2018 Academy Election is open. Remember to vote!

2018 QCDR measures

AAD QCDR ID Measure name Description Steward Type of measure NQS Domain
 1 Psoriasis: Assessment of Psoriasis Disease Activity
Percentage of patients with plaque psoriasis who have disease activity assessed by using one of the listed measures or validated instruments/ tools* at least once during the measurement period.
* Assessment and classification of disease activity using standardized descriptive measures or tools resulting in a numeric score or composite index: Scales and instruments are examples and cut‐points can differ by scale. Standardized descriptive or numeric scales and/or composite indexes include: Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), Physician’s Global Assessment (PGA), Dermatology Life Quality Index (DLQI).
 AAD  Process   Effective Clinical Care
 
 2 Psoriasis: Screening for Psoriatic Arthritis
Percentage of patients with diagnosis of psoriasis who are screened for psoriatic arthritis at least once during the measurement period.  AAD    Person & Caregiver-Centered Experience & Outcomes
 3 Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Superficial Basal Cell Carcinoma of the Trunk for Immune Competent Patients
The percentage of immune‐competent patients with pathologically‐proven primary superficial basal cell carcinoma (BCC) lesions on the trunk (chest, back, abdomen) who are treated with Mohs surgery.  AAD  Process  Efficiency and Cost Reduction
 4 Basal Cell Carcinoma/Squamous Cell Carcinoma: Mohs Surgery for Squamous Cell Carcinoma in Situ or Keratoacanthoma Type Squamous Cell Carcinoma 1 cm or Smaller on the Trunk
The percentage of immune‐competent patients with pathologically‐proven primary squamous carcinoma in situ (SCCis) lesions of any size on the trunk (chest, back, abdomen) or keratoacanthoma type squamous cell carcinoma (ASCC‐KA) lesions 1 cm or smaller on the trunk (chest, back, abdomen) who are treated with Mohs surgery.   AAD  Process  Efficiency and Cost Reduction
 5 Biopsy: Reporting Time – Clinician to Patient
Percentage of patients with skin biopsy specimens with a diagnosis of cutaneous basal or squamous cell carcinoma (including in situ disease) who are notified of their final biopsy pathology findings within less than or equal to 14 days from the time the biopsy was performed.   AAD  Process Communication and Care Coordination

 

©American Academy of Dermatology/Association. All rights reserved. The American Academy of Dermatology and the American Academy of Dermatology Association (collectively AAD/A) own all right, title, and interest in the quality measurespresented on these web pages. These quality measures are provided solely for the benefit of AAD/A and its members for the purposes specified herein and for other AAD/A purposes. They may not be used by other parties except with prior written approval of the AAD/A.